$JAGX earnings report

Jaguar Health Q3 2026: total revenue down 24.0% to $2,343 thousand as product revenue fell 81.9%; net loss narrowed 39.6% to $(5,830) thousand after the Future Pak licensing deal and lower operating costs. AlphAI read Jaguar Health's Q3 FY2026 filing as mixed.

Q3 FY2026

AlphAI · Earnings readJAGX · Q3 2026 · ended 2026-09-30

Jaguar Health Q3 2026: total revenue down 24.0% to $2,343 thousand as product revenue fell 81.9%; net loss narrowed 39.6% to $(5,830) thousand after the Future Pak licensing deal and lower operating costs

→Mixed quarter

Total revenue fell 24.0% and product revenue fell 81.9% year over year, with prescription product revenue now largely cost-plus sales to Future Pak. Against that, license and grant revenue rose to $1,792 thousand, loss from operations narrowed 16.8%, net loss narrowed 39.6%, and the company reports a debt balance reduction of $10.1 million in Q3 2026.

Revenue
$2.34M
-24.0% y/y
License and grant revenue, net
$1.79M
4166.7% y/y
EPS · GAAP
$(9.23)
99.5% y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, net (Q3 2026)GAAP$2.34M–-24.0%
License and grant revenue, net (Q3 2026)GAAP$1.79M–4166.7%
Product revenue, net (Q3 2026)GAAP$551K–-81.9%
Loss from operations (Q3 2026)GAAP−$6.02M–16.8%
Net loss (Q3 2026)GAAP−$5.83M–39.6%
Net loss per share, basic and diluted (Q3 2026)GAAP$(9.23)–99.5%
Non-GAAP Recurring EBITDA (Q3 2026)non-GAAP−$5.03M–44.2%
Non-GAAP EBITDA (Q3 2026)non-GAAP−$5.59M–38.1%
Cost of product revenue (Q3 2026)otherabout $0.6 million–increased by $0.1 million
Research and development expense (Q3 2026)other$3.6M–decreased by approximately $0.1 million
Sales and marketing expense (Q3 2026)otherapproximately $51,000–decreased by approximately $1.95 million
General and administrative expense (Q3 2026)other$4M–decreased by approximately $55,000
Interest income (expense) (Q3 2026)other$156,000 interest expense–increased by $150,000
Fair value option (FVO) instrument designation result (Q3 2026)otherloss of $96,000–decreased by about $2.2 million
Gain on extinguishment of debt (Q3 2026)other$600K–increased by $0.6 million
Prescription product net revenue (Mytesi, Gelclair, Canalevia-CA1) (Q3 2026)otherapproximately $0.5 million––
License fees from securities purchase agreement with European partner (Q3 2026)other$42,000––
Federal grant revenue (nine months ended September 30, 2026)other$25,000––

Segments

SegmentRevenueq/qy/y
License and grant revenue, netCompany states that Jaguar entered a U.S. commercial licensing agreement with Woodward Specialty, LLC, an affiliate of privately held Future Pak, LLC, effective January 12, 2026, and that license fees of $42,000 were recognized in Q3 2026 under a securities purchase agreement with a European partner. The filing does not itemize the remainder of the $1,792 thousand.$1.79M–4166.7%
Product revenue, net (prescription products: Mytesi, Gelclair, Canalevia-CA1)Company states the Q3 2026 prescription product revenue was comprised primarily of sales of Mytesi at cost-plus to Future Pak. Under the royalty-free license agreement, all U.S. revenues from Mytesi and Canalevia-CA1 from January 12, 2026 are directed to Future Pak, which does not report Mytesi sales. Company states the Q3 2026 Mytesi bottles sold increased significantly versus Q3 2025 and commercial costs were substantially decreased. Prescription product revenue was approximately $1.2 million in Q2 2026 and approximately $3.0 million in Q3 2025.$551 thousand (prescription products approximately $0.5 million)–-81.9%
Neonorm (non-prescription)Company states revenues for the non-prescription Neonorm products were consistent and minimal for the third quarters of 2026 and 2025.Consistent and minimal in Q3 2026 and Q3 2025 (no figure printed)––

What drove it

  • Company states the Q3 2026 Mytesi and Canalevia-CA1 U.S. commercialization was licensed to Future Pak, with the company now operating as a distribution entity and manufacturer supplying product at cost-plus terms.
  • Company states the dissolution of the Jaguar/Napo Sales and Marketing Group as of January 12, 2026, following the licensing to Future Pak, was the driver of the sales and marketing expense decrease.
  • Company states R&D increased $0.8 million for clinical trials and development of crofelemer into a powder formulation (lyophilization), offset by a $0.9 million decrease from reductions in force (RIF), third-party consulting and other expense due to conclusion of the CTD Phase 3 clinical trial.
  • Company states G&A increased $0.6 million for legal and public services, audit, accounting and tax services, and stock-based compensation, offset by a $0.7 million decrease in consulting, lease, travel and other expense.
  • Company states the loss from operations decrease was primarily due to a $0.7 million decrease in total net revenue, offset by a reduction in operating expenses of approximately $2.0 million, attributed to the Future Pak licensing agreement.
  • Company states the FVO result improved primarily due to lower outstanding carrying amounts of royalty interests and notes payable designated at FVO relative to their fair values, resulting in lower fair value changes during the period.
  • Company states the gain on extinguishment of debt of $0.6 million was primarily attributable to the extinguishment of the Streeterville New Note following the exchange transaction.
  • Company states interest expense increased due to interest expenses accrued on notes.

Concerns

  • Total revenue fell 24.0% to $2,343 thousand and product revenue fell 81.9% to $551 thousand year over year.
  • Loss from operations of $(6,023) thousand and net loss of $(5,830) thousand remain negative in Q3 2026.
  • Non-GAAP EBITDA of $(5,590) thousand and Non-GAAP Recurring EBITDA of $(5,032) thousand remain negative.
  • Company states Future Pak is privately held and does not report Mytesi sales, which limits the visibility of U.S. product sales.
  • Interest expense rose to $156,000 from $6,000 of interest income in the prior-year quarter, which company attributes to interest accrued on notes.
  • Q3 2026 license and grant revenue of $1,792 thousand is largely not itemized in the filing beyond the $42,000 of license fees, so the composition of the figure cannot be confirmed from this document.

What to watch

  • Planned New Drug Application (NDA) filing for crofelemer for MVID, which the company expects in mid-2027.
  • Investor webcast on Tuesday, November 17, 2026 at 8:30 a.m. Eastern regarding Q3 2026 financials and company updates.
  • Continued debt reduction following the $10.1 million reduction in Q3 2026.
  • Operating expense trajectory now that the Future Pak licensing agreement has removed the Jaguar/Napo sales and marketing group.
  • Progress of the crofelemer powder-for-oral-solution clinical program for rare intestinal failure indications, including the clinical milestones the company describes.

Balance sheet and cash flow

  • Company states it significantly reduced its outstanding debt balance by $10.1 million in Q3 2026.
  • Company states the Streeterville New Note was fully repaid and cancelled following an exchange transaction in which Jaguar issued shares of common stock to Streeterville.
  • Total deferred revenue associated with the European partner contract was $425,000 as of September 30, 2026.
  • Company states that, as announced in August 2026, it satisfied the closing conditions required to receive payment of the non-dilutive approximately $1.8 million holdback amount of the upfront fee from Future Pak. The filing does not state that the holdback was received in cash.

Analysis

Jaguar Health reported Q3 2026 total revenue, net of $2,343 thousand, down 24.0% from $3,083 thousand in Q3 2025. The mix changed sharply. License and grant revenue, net rose to $1,792 thousand from $42 thousand, while product revenue, net fell 81.9% to $551 thousand from $3,041 thousand. The company states that its prescription product revenue of approximately $0.5 million was comprised primarily of Mytesi sales at cost-plus to Future Pak under the licensing agreement effective January 12, 2026, and that Future Pak does not report Mytesi sales. The filing identifies the $42,000 of Q3 2026 license fees from a European partner, but it does not break down the rest of the $1,792 thousand license and grant line, so the reader cannot tell how much of that figure is recurring.

Operating costs moved in the same direction as the restructured commercial model. Sales and marketing expense fell to approximately $51,000 from $2.0 million, and the company attributes this to the dissolution of the Jaguar/Napo Sales and Marketing Group. R&D was $3.6 million against $3.7 million, with the company citing a $0.8 million increase for lyophilization and clinical work offset by a $0.9 million decrease from reductions in force and the conclusion of the CTD Phase 3 trial. G&A was $4.0 million against $4.1 million. Loss from operations narrowed to $(6,023) thousand from $(7,238) thousand, a 16.8% improvement, and net loss narrowed to $(5,830) thousand from $(9,648) thousand, a 39.6% improvement. Net loss per share was $(9.23) against $(2,032.95) in the prior-year quarter as printed.

Below-the-line items contributed to the net loss change. The fair value option result improved to a loss of $96,000 from a loss of $2.3 million, which the company attributes to lower carrying amounts of royalty interests and notes payable designated at FVO. A gain of $0.6 million on extinguishment of debt followed the exchange transaction that repaid and cancelled the Streeterville New Note through the issuance of common stock. Interest expense rose to $156,000 from $6,000 of interest income. Non-GAAP EBITDA was $(5,590) thousand against $(9,025) thousand, and Non-GAAP Recurring EBITDA was $(5,032) thousand against $(9,025) thousand, with both measures excluding the gain on extinguishment in the Non-GAAP EBITDA reconciliation.

Balance sheet items are limited. The company states that it significantly reduced its outstanding debt by $10.1 million in Q3 2026, that deferred revenue on the European partner contract was $425,000 at September 30, 2026, and that it satisfied the closing conditions to receive an approximately $1.8 million holdback from Future Pak. The filing does not print cash, total debt, total assets, equity or operating cash flow, and it contains no forward guidance for revenue, margins or expenses. The main attention points are the 24.0% revenue decline, the 81.9% drop in product revenue, the continued operating and net losses, and the reliance on a licensing partner for U.S. product sales that the company says does not report Mytesi volumes. The company's stated next milestone is an NDA filing for crofelemer for MVID in mid-2027.

Not in the filing

stated, not guessed
  • No forward guidance for revenue, gross margin, operating expenses or tax rate is provided in the document, and no prior outlook was supplied for comparison.
  • Consolidated prior-quarter (Q2 2026) totals for total revenue, license and grant revenue, product revenue, operating loss and net loss are not printed; only Q2 2026 prescription product revenue (approximately $1.2 million) appears in the text.
  • Sequential (qoq) and change-on-change figures for the prescription product revenue line are not printed and were not computed.
  • Non-GAAP net loss per share and other non-GAAP measures beyond Non-GAAP EBITDA and Non-GAAP Recurring EBITDA are not printed.
  • Cash and cash equivalents, total debt balance, total assets, total equity, operating cash flow and free cash flow are not printed.
  • No share repurchases, dividends or other capital returns are printed in the document.
  • Composition of the $1,792 thousand license and grant revenue beyond the $42,000 of license fees is not itemized.
  • The company's narrative prints the prior-year quarter as 'September 31, 2025', which is not a valid calendar date; the figures are presented as the third quarter of 2025.
  • Neonorm revenue is described only as consistent and minimal, with no figure printed for either quarter.
  • Share price reaction, consensus estimates and analyst expectations are not included in the filing and were not used.
  • Quotes from named executives are not included in the document.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about JAGX earnings dates

When is Jaguar Health's next earnings date?
AlphAI has no date for JAGX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.